Clinical Usefulness of Arbekacin.
Jae-Hoon LeeChang Seop LeePublished in: Infection & chemotherapy (2016)
Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin has antibacterial activities against high-level gentamicin-resistant Enterococci, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii et al. Here, we reviewed in vitro data on arbekacin in Staphylococci and Gram-negative microorganisms. We also reviewed clinical studies for clinical efficacy and microbiologic efficacy data in patients with identified MRSA and suspected MRSA infections. The overall clinical efficacy ranged from 66.7% to 89.7%. The microbiologic efficacy rate ranged from 46.2% to 83%. In comparative studies between arbekacin and glycopeptides, arbekacin was similar to other glycopeptides with respect to clinical and microbiological efficacy rates. Combination trials with other antibiotics suggest that arbekacin will be a promising strategy to control Enterococcus spp. multi-drug resistant P. aeruginosa. The major adverse reaction was nephrotoxicity/hepatotoxicity, but patients recovered from most adverse reactions without any severe complications. Based on these results, arbekacin could be a good alternative to vancomycin/teicoplanin in MRSA treatment. Finally, therapeutic drug monitoring is recommended to maximize clinical efficacy and decrease nephrotoxicity.
Keyphrases
- methicillin resistant staphylococcus aureus
- multidrug resistant
- acinetobacter baumannii
- drug resistant
- gram negative
- staphylococcus aureus
- pseudomonas aeruginosa
- klebsiella pneumoniae
- newly diagnosed
- biofilm formation
- end stage renal disease
- electronic health record
- prognostic factors
- drug induced
- big data
- ejection fraction
- chronic kidney disease
- early onset
- cystic fibrosis
- peritoneal dialysis
- risk factors
- case control
- candida albicans
- machine learning
- data analysis
- smoking cessation
- emergency department